We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Angiotensin II Type 1 Receptor Antagonists on the Size and Expansion Rate of Abdominal Aortas in Hypertensive Patients

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2012 by Dr. Daniel Silverberg, Sheba Medical Center.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01670903
First Posted: August 22, 2012
Last Update Posted: August 22, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Dr. Daniel Silverberg, Sheba Medical Center
  Purpose

Abdominal aortic aneurysm (AAA) is a common disease that develops from degeneration of the aortic wall. The natural history of AAA is gradual expansion and if left untreated may result in rupture and death. The mechanism of the development of this disease is unknown however it appears to be multifactorial and possibly related to degradation processes within the arterial wall. There is growing evidence that Angiotensin receptor blockers ( ARBS) may have an inhibitory effect on remodelling processes within the arterial wall, thus inhibiting degeneration of the vessel wall.

Study hypothesis: ARBS are associated with smaller diameters of aortas among hypertensive patients, and are associated with a lower rate of aortic expansion compared to other antihypertensive drugs.


Condition
Aneurysm Hypertension

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: the Effect of Angiotensin II Type 1 Receptor Antagonists on the Size and Expansion Rate of Abdominal Aortas in Hypertensive Patients

Resource links provided by NLM:


Further study details as provided by Dr. Daniel Silverberg, Sheba Medical Center:

Estimated Enrollment: 150
Study Start Date: May 2011
Groups/Cohorts
ARBs
Hypertensive patients treated with ARBs
ACE inhibitors
Hypertensive patients treated with ACE inhibitors
non ARB/ACE
Hypertensive patients treated with non ARBs or ACE inhibitors meds

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
medically treated hypertensive patients, ages 50-80
Criteria

Inclusion Criteria:

  • medically treated hypertensive patients, ages 50-80

Exclusion Criteria:

  • pregnant women
  • patients previously treated for aortic disease
  • unable to sign informed consent, minors
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01670903


Contacts
Contact: Daniel Silverberg, MD 035302712 Daniel.Silverberg@sheba.health.gov.il

Locations
Israel
Sheba Medical Center Recruiting
Tel Hashomer, Israel
Sub-Investigator: Jacob Schneiderman, MD         
Sub-Investigator: Ehud Grossman, MD         
Sub-Investigator: Moshe Halak, MD         
Sub-Investigator: Anan Younes, MD         
Sub-Investigator: Dmitry Yakubovitz, MD         
Sub-Investigator: Bashir Sheik-yosef, MD         
Sub-Investigator: Ronnie E Reinitz, MD         
Sheba Medical Center Recruiting
Tel Hashomer, Israel
Contact: Daniel Silverberg, MD       Daniel.Silverberg@sheba.health.gov.il   
Sponsors and Collaborators
Sheba Medical Center
Investigators
Principal Investigator: Daniel Silverberg, MD Sheba Medical Center
  More Information

Responsible Party: Dr. Daniel Silverberg, Senior consultant - Vascular surgery, Sheba Medical Center
ClinicalTrials.gov Identifier: NCT01670903     History of Changes
Other Study ID Numbers: SHEBA-12-8336-DS-CTIL
First Submitted: August 19, 2012
First Posted: August 22, 2012
Last Update Posted: August 22, 2012
Last Verified: August 2012

Additional relevant MeSH terms:
Aneurysm
Vascular Diseases
Cardiovascular Diseases
Angiotensin-Converting Enzyme Inhibitors
Angiotensin II
Angiotensinogen
Angiotensin II Type 1 Receptor Blockers
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Vasoconstrictor Agents
Serine Proteinase Inhibitors
Angiotensin Receptor Antagonists